Literature DB >> 12172658

Suppressive effect of vagal afferents on cervical dorsal horn neurons responding to tooth pulp electrical stimulation in the rat.

T Tanimoto1, M Takeda, S Matsumoto.   

Abstract

The aim of the present study was to test the hypothesis that vagal afferent (VA) inputs modify the tooth pulp (TP) stimulation-evoked activity of the first cervical dorsal horn (C1) neurons via the activation of endogenous noradrenergic and serotonergic systems. In 30 anesthetized rats, the activity of 56 C1 spinal neurons and the amplitude in a digastric muscle electromyogram (dEMG, n=30) increased proportionally during TP stimulation at an intensity of 1-3.5 times the threshold for the jaw-opening reflex (JOR). The activity in 46 of these C1 neurons (82.1%) was suppressed by VA stimulation (1.0 mAx0.1 ms, 50 Hz for 30 s) of the right vagus nerve. The suppressive effects of VA stimulation on C1 spinal neuron activity were significantly reduced after intravenous administration of either the alpha-adrenergic receptor antagonist phenoxybenzamine (POB, 2.0 mg/kg and 4.0 mg/kg) or the 5-hydroxytryptamine-3 (5-HT(3)) receptor antagonist ICS 205-930 (1.0 mg/kg and 2.0 mg/kg). But the 5-HT(1/2) receptor antagonist methysergide (1.0 mg/kg and 2.0 mg/kg) had no significant effect on VA stimulation-induced inhibition of the C1 spinal neuron activity. These results suggest that VA stimulation inhibits nociceptive transmission in the C1 spinal neuron activity via the activation of both noradrenergic and serotonergic (5-HT(3)) descending inhibitory systems.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12172658     DOI: 10.1007/s00221-002-1138-1

Source DB:  PubMed          Journal:  Exp Brain Res        ISSN: 0014-4819            Impact factor:   1.972


  8 in total

1.  N-methyl-D-aspartate (NMDA) and non-NMDA receptor antagonists suppress the superior sagittal sinus-evoked activity of C1 spinal neurons responding to tooth pulp electrical stimulation in rats.

Authors:  Yoshinobu Fujimi; Mamoru Takeda; Takeshi Tanimoto; Shigeji Matsumoto
Journal:  Odontology       Date:  2006-09       Impact factor: 2.634

2.  Prostaglandin E2 potentiates the excitability of small diameter trigeminal root ganglion neurons projecting onto the superficial layer of the cervical dorsal horn in rats.

Authors:  Jun Kadoi; M Takeda; S Matsumoto
Journal:  Exp Brain Res       Date:  2007-01       Impact factor: 1.972

3.  Activation of alpha2-adrenoreceptors suppresses the excitability of C1 spinal neurons having convergent inputs from tooth pulp and superior sagittal sinus in rats.

Authors:  M Takeda; T Tanimoto; M Takahashi; J Kadoi; M Nasu; S Matsumoto
Journal:  Exp Brain Res       Date:  2006-04-08       Impact factor: 1.972

4.  Somatostatin inhibits tooth-pulp-evoked rat cervical dorsal horn neuronal activity.

Authors:  M Takahashi; M Takeda; S Matsumoto
Journal:  Exp Brain Res       Date:  2008-01-09       Impact factor: 1.972

5.  Noninvasive vagus nerve stimulation and morphine transiently inhibit trigeminal pain signaling in a chronic headache model.

Authors:  Lauren E Cornelison; Jordan L Hawkins; Sara E Woodman; Paul L Durham
Journal:  Pain Rep       Date:  2020-12-17

6.  Vagus nerve stimulation inhibits trigeminal nociception in a rodent model of episodic migraine.

Authors:  Jordan L Hawkins; Lauren E Cornelison; Brian A Blankenship; Paul L Durham
Journal:  Pain Rep       Date:  2017-10-17

7.  Effect of Non-invasive Vagus Nerve Stimulation on Resting-State Electroencephalography and Laser-Evoked Potentials in Migraine Patients: Mechanistic Insights.

Authors:  Eleonora Vecchio; Iege Bassez; Katia Ricci; Cristina Tassorelli; Eric Liebler; Marina de Tommaso
Journal:  Front Hum Neurosci       Date:  2018-09-13       Impact factor: 3.169

8.  Inhibition of Trigeminal Nociception by Non-invasive Vagus Nerve Stimulation: Investigating the Role of GABAergic and Serotonergic Pathways in a Model of Episodic Migraine.

Authors:  Lauren E Cornelison; Sara E Woodman; Paul L Durham
Journal:  Front Neurol       Date:  2020-03-05       Impact factor: 4.003

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.